Page last updated: 2024-09-03

n-benzyladriamycin-14-valerate and epirubicin

n-benzyladriamycin-14-valerate has been researched along with epirubicin in 1 studies

Compound Research Comparison

Studies
(n-benzyladriamycin-14-valerate)
Trials
(n-benzyladriamycin-14-valerate)
Recent Studies (post-2010)
(n-benzyladriamycin-14-valerate)
Studies
(epirubicin)
Trials
(epirubicin)
Recent Studies (post-2010) (epirubicin)
25035,4531,8381,570

Protein Interaction Comparison

ProteinTaxonomyn-benzyladriamycin-14-valerate (IC50)epirubicin (IC50)
Genome polyprotein 0.75
Tyrosine-protein kinase FynHomo sapiens (human)5.181

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dockter, M; Hosey, LM; Koseki, Y; Lothstein, L; Priebe, W; Sweatman, TW1

Other Studies

1 other study(ies) available for n-benzyladriamycin-14-valerate and epirubicin

ArticleYear
N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
    Oncology research, 1993, Volume: 5, Issue:6-7

    Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Doxorubicin; Drug Resistance; Epirubicin; Membrane Glycoproteins; Mice; Structure-Activity Relationship; Tumor Cells, Cultured

1993